Read More

Dyne Therapeutics Announced Clinical Data From Its Ongoing Phase 1/2 ACHIEVE Trial Of DYNE-101 In Myotonic Dystrophy Type 1 And Phase 1/2 DELIVER Trial Of DYNE-251 In Duchenne Muscular Dystrophy

In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months DYNE-101 Showed Improvement in Myotonia, Muscle Strength, and Timed

DYN